We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
The Mission Marketing Group Plc | LSE:TMMG | London | Ordinary Share | GB00B11FD453 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 78.50 | 77.00 | 80.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
11/3/2016 18:25 | I have to say the rating on this share confuses me. They deliver what they say they will each year (in recent times) and despite that we've gone nowhere! Presuming results are once again as promised and the forward statement ok then I am positive we will re-rate at some point. I'm a patient man...I need to be. IMO. | red_shed2000 | |
11/3/2016 16:07 | CLL turning very blue ahead of what I believe must be results v. soon? DYOR etc | qs99 | |
08/3/2016 11:17 | A few buy's and chart turning up in the run up to premlims on the 22nd ! | cheshire man | |
03/3/2016 08:36 | and CLL now moving up nicely, hope a few of you got in from my post 26 Feb...? | qs99 | |
26/2/2016 12:41 | if you like this one, take a look at CLL...results due out in March I believe DYOR | qs99 | |
15/2/2016 11:23 | all the forecasts are for eps 5.6p then 6.1 p, very modest rating. Great new clients - Ask, Br Airways, Diageo, BMW, RAC, Siemens etc etc. But continues to be unloved. Patience needed. tempted to top up at 39P | puku | |
29/1/2016 15:54 | Or someone else will come in and snap it up....IMO.... | qs99 | |
26/1/2016 12:05 | Uopdate last week didn't seem to help much. PE of 6 has got to be one the lowest around. Just needs better PR - does anyone know a good company that can help.... | dr biotech | |
22/1/2016 12:37 | defo looks interesting IMO vs its peers.... EV/EBITDA 4.2 is IMO not pushing it! | qs99 | |
22/1/2016 10:07 | Thanks db. 60p seems a reasonable target. | penpont | |
22/1/2016 09:52 | Finncap; The Mission Marketing Group*: Trading update (CORP) The group has issued a trading update for the year to December 2015. The statement confirms that the group has performed well throughout the second half of the financial year and that recent acquisitions are trading well. As a result, final results will be in line with market expectations. The finnCap forecast is for an adjusted PBT of £6.4m, which implies an H2 adjusted PBT of £4.22m. The statement also confirms that net debt will have increased on the last year-end level as a result of the acquisitions, but that the gearing and debt leverage ratios will be broadly unchanged year-on-year and well within internal targets. Following the statement, our 2016 forecast adjusted PBT remains unchanged at £7.4m. At the current 40p share price, the implied 2016 valuation metrics include EV/EBITDA of 4.2x, a PE of 6.0x and a yield of 3.2%. We view this as good value given the forward growth profile and retain our 60p share price target. Final results are expected on 22 March. Analyst: Mark Paddon | davebowler | |
22/1/2016 08:30 | Reassuring update. Good to see comment re. further progress in current year too. V lowly valued. | penpont | |
14/1/2016 11:11 | good buying opportunity | mfhmfh | |
02/1/2016 14:46 | Growth mentioned frequently in this part of the business:- | jeff h | |
22/12/2015 21:50 | David Morgan sounding confident though doesn't actually say much:- | jeff h | |
18/12/2015 13:37 | Yes it does look cheap.I'm in. | davebowler | |
16/12/2015 13:49 | Looks UV IMO vs its peers....next RNS may help give it a kick start IMO... | qs99 | |
16/12/2015 12:30 | Yes like the look of this and have started to add a few as well...DYOR etc | qs99 | |
16/12/2015 12:08 | Agree re: valuation, JH - and I like that the CERN contract is being handled by two of the group companies - Proof and April6. Cross selling and inter group collaboration is often cited as a potential advantage but I suspect rarely delivers all that it could. I've bought back in with a small investment today. DYOR | cliffpeat | |
16/12/2015 10:15 | Looks quite a decent contract win:- | jeff h | |
16/12/2015 08:20 | DB whilst there has been no change in the 2015 forecast, 2016 has been increased to reflect the Chapter acquisition. 2016 Old Pbt £7.0m EPS 6.1p 2016 New Pbt £7.4m EPS 6.6p A P/E of approx. 6.2 then at the current 41p share price. Too cheap on the face of it and I've added some this am. | jeff h | |
15/12/2015 14:51 | There has been no change in the broker forecasts - I can't see any reason for this sharp fall. Just illiquid I guess | dr biotech | |
09/12/2015 16:32 | They also announced another deal today - not sure why that wasn't a standard RNS. Perhaps the value is small I'd hope they had not paid a significant amount for a company that has only just formed. Floor seems to be 40p, I was hoping for better things. | dr biotech |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions